Molecular Modifications of the Pseudomonas Quinolone Signal In

Total Page:16

File Type:pdf, Size:1020Kb

Molecular Modifications of the Pseudomonas Quinolone Signal In Journal of Fungi Article Molecular Modifications of the Pseudomonas Quinolone Signal in the Intermicrobial Competition with Aspergillus Hasan Nazik 1,†,‡, Gabriele Sass 1,†, Paul Williams 2 , Eric Déziel 3 and David A. Stevens 1,4,* 1 Infectious Diseases Research Laboratory, California Institute for Medical Research, San Jose, CA 95128, USA; [email protected] (H.N.); [email protected] (G.S.) 2 Biodiscovery Institute and School of Life Sciences, University of Nottingham, Nottingham NG7 2RD, UK; [email protected] 3 Centre Armand-Frappier Santé Biotechnologie, Institut National de la Recherche Scientifique (INRS), Laval, QC H7V 1B7, Canada; [email protected] 4 Division of Infectious Diseases and Geographic Medicine, Stanford University Medical School, Stanford, CA 94305, USA * Correspondence: [email protected]; Tel.: +1-408-998-4554 † These authors contributed equally to this work. ‡ Current address: National University of Health Sciences, Pinellas Park, FL 33781, USA. Abstract: The Pseudomonas quinolone signal (PQS) is an important quorum-sensing molecule for Pseudomonas aeruginosa that regulates virulence factors, chelates iron, and is an important factor in interactions with eukaryotes, including fungi and mammalian hosts. It was previously shown to inhibit or boost Aspergillus, depending on the milieu iron concentration. We studied several molecular modifications of the PQS molecule, and their effects on Aspergillus biofilm metabolism and growth in vitro, and the effects of iron supplementation. We found that most molecules inhibited Aspergillus at concentrations similar to that of PQS, but with relatively flat dose-responses, and Citation: Nazik, H.; Sass, G.; all were less potent than PQS. The inhibition was reversible by iron, suggesting interference with Williams, P.; Déziel, E.; Stevens, D.A. fungal iron metabolism. Stimulation of Aspergillus was not noted. We conclude that the critical Molecular Modifications of the Aspergillus-inhibiting moeities of the PQS molecule were partially, but not completely, interfered Pseudomonas Quinolone Signal in with by molecular modifications at several sites on the PQS molecule. The mechanism, as with PQS, the Intermicrobial Competition with appears to relate to fungal iron metabolism. Aspergillus. J. Fungi 2021, 7, 343. https://doi.org/10.3390/jof7050343 Keywords: Aspergillus; Pseudomonas; Pseudomonas quinolone signal; intermicrobial competition Academic Editor: David S. Perlin Received: 16 March 2021 1. Introduction Accepted: 21 April 2021 Published: 28 April 2021 Pseudomonas aeruginosa (Pa) and Aspergillus fumigatus (Af) encounter each other in nature in soil and water, and are, in most studies, the most frequently found bacterium Publisher’s Note: MDPI stays neutral and fungus in the airways of immunocompromised hosts, including persons with cystic with regard to jurisdictional claims in fibrosis (CF) [1,2]. Thus, it is expected that these two microbes likely compete for their published maps and institutional affil- establishment and growth in various milieu. This has been studied extensively in vitro, iations. and to a lesser extent in animal models, a subject reviewed in detail elsewhere [3–9]. Among the molecules identified in the intermicrobial competition is 2-heptyl-3- hydroxy-4(1H)-quinolone, the Pseudomonas Quinolone Signal (PQS). PQS is a quorum- sensing molecule, coordinating many Pa functions [8,10]. It chelates iron (Fe) and delivers Copyright: © 2021 by the authors. it to the bacterial cell membrane in conjunction with Pa siderophores [10–13]. It upregulates Licensee MDPI, Basel, Switzerland. genes involved in Pa oxidative stress responses, but can also be a pro-oxidant and induce This article is an open access article oxidative stress; it regulates Pa virulence factors, and in intermicrobial interactions it can distributed under the terms and be used as a quorum sensing signal by other bacterial species, inhibit the respiratory chain, conditions of the Creative Commons or induce membrane vesicle formation in other bacteria; and it can be inactivated by other Attribution (CC BY) license (https:// bacteria [14–16]. Relevant to eukaryotes, PQS production can be inhibited by fungi, and in creativecommons.org/licenses/by/ contrast, PQS can inhibit fungal biofilm formation [14,15,17,18]. In eukaryotic hosts, PQS 4.0/). J. Fungi 2021, 7, 343. https://doi.org/10.3390/jof7050343 https://www.mdpi.com/journal/jof J. Fungi 2021, 7, x FOR PEER REVIEW 2 of 17 J. Fungi 2021, 7, 343 2 of 16 fungi, and in contrast, PQS can inhibit fungal biofilm formation [14,15,17,18]. In eukary- oticcan hosts, be toxicPQS tocan host be cells,toxic andto host impair cells, host and defenses impair host [12,14 defenses,19]. Its probable[12,14,19] relevance. Its probablein vivo relevanceis heightened in vivo byis heightened reports of its by presence reports of in its body presence fluids in of body patients flui [ds12 of,14 patients]. [12,14]. In aIn previous a previous study study [18], [18 we], wefocused focused on onPQS PQS inhibition inhibition of Af of Afbiofilm biofilm metabolism metabolism in a in a lowlow Fe Feenvironment environment (RPMI (RPMI-1640-1640 medium), medium), and and in in ancillary ancillary experiments, experiments, PQS PQS inhibited Af Af growth on on agar agar as as well. well. The The biofilm biofilm inhibition inhibition was was reversed reversed by by the the addition addition of ofFe. Fe. Most Most remarkably,remarkably, and and paradoxically, paradoxically, in in an an enriched enriched Fe Fe environment, environment, PQS PQS + + Fe Fe boosted boosted Af biofilmbio- filmmetabolism, metabolism, as as well well as as planktonic planktonic Af Af growth growth and and growth growth on on agar. agar. This This boosting boosting exceeded ex- ceededthe boosting the boosting effect effect of Fe of alone. Fe alone. Perhaps Perhaps uniquely uniquely biologically, biologically, the maximum the maximum boosting boost- effect ingrequired effect required Af siderophore Af siderophore involvement. involvement. ResearchResearch (with (with some some interest interest in inthe the possibility possibility of of generating generating inhibitors inhibitors of of Pa) Pa) in in sev- several erallaboratories, laboratories studying, studying molecular molecular modifications modifications of of the the PQS PQS molecule, molecule has, has indicated indicated a higha highdegree degree of of structural structural PQS PQS specificityspecificity forfor its functions functions in in Pa Pa physiology physiology [17,20,21] [17,20,21. ].We We thereforetherefore studied studied whether whether such such congeners congeners would would act actsimilarly similarly to PQS to PQS in the in theintermicrobial intermicrobial interactionsinteractions des describedcribed for forPQS. PQS. The The chemical chemical formulae formulae for forthe themolecules molecules studied studied are aregiven given in Figurein Figure 1 [20,221[20,22]. ]. Figure 1. Molecules in this study. In all, R1 is an H atom. In Pseudomonas quinolone signal (PQS), Figure 1. Molecules in this study. In all, R1 is an H atom. In Pseudomonas quinolone signal (PQS), 2-heptyl-4-hydroxyquinoline (HHQ), 2-heptyl-3-chloro-4(1H)-quinolone (3Cl-PQS) and 2-heptyl-3- 2-heptyl-4-hydroxyquinoline (HHQ), 2-heptyl2 -3-chloro-4(1H)-quinolone (3Cl-PQS) and 2-heptyl-3- amino-4(1H)-quinolone (3NH2-PQS)2 R is an alkyl side chain, C7H15. In C1-PQS, C3-PQS, C5-PQS, amino-4(1H)-quinolone (3NH2-PQS) R is an alkyl side chain, C7H15. In C1-PQS, C3-PQS, C5-PQS, 2 andand C9-PQS C9-PQS R2 is R anis alkyl an alkyl side sidechain chain of 1, of3, 5 1,, and 3, 5, 9 and carbon 9 carbon molecules, molecules, respectively. respectively. In PQS In and PQS and 3 3 HHQ,HHQ, R3 is R a ishydroxyl a hydroxyl group group or an or anH atom, H atom, respectively. respectively. In In3Cl 3Cl-PQS-PQS and and 3NH 3NH2-PQS,2-PQS, R3 R is isa chlo- a chlorine rineor or primary primary amine amine group, group, respectively. respectively. HHQHHQ (2-heptyl (2-heptyl-4-hydroxyquinoline)-4-hydroxyquinoline) is a is PQS a PQS precursor, precursor, and and it also it also activate activatess the thetran- tran- scriptionalscriptional regulator regulator PqsR PqsR (also (also known known as M asvfR) MvfR) [20] [ 20(2-]heptyl (2-heptyl-3-amino-4(1-3-amino-4(1H)-Hquinolone)-quinolone,, 3NH3NH2-PQS2-PQS retains retains this this capability capability).). PqsR PqsR is the is thePa protein Pa protein that that plays plays a central a central role role in the in the alkylalkyl quinolone quinolone-dependent-dependent quorum quorum-sensing-sensing cascade, cascade, and and is a isregulator a regulator of multiple of multiple viru- viru- lence factors (recently reviewed in [8]). The NH group is isosteric with OH, but would lence factors (recently reviewed in [8]). The NH2 group2 is isosteric with OH, but would havehave opposite opposite electronic electronic effects effects on onthe the bicyclic bicyclic ring. ring. 2-Heptyl 2-Heptyl-3-chloro-4(1-3-chloro-4(1H)-Hquinolone)-quinolone (3Cl(3Cl-PQS)-PQS) is unable is unable to toactivate activate PqsR, PqsR, and and the the 3- 3-ClCl substitution substitution will will have have different different molecularmolec- ulareffects effects than than the the 3-OH 3-OH on on the the bicyclic bicyclic ring. ring. ModificationsModifications ofof thethe 2-alkyl2-alkyl sideside chain,chain, ofof all all the substitutions, would be likely to retain Fe Fe-chelating-chelating properties of of PQS PQS ( (inin contrast contrast to 3NH2-PQS and 3Cl-PQS that lack the adjacent oxygen molecules at the 3 and 4 positions to 3NH2-PQS and 3Cl-PQS that lack the adjacent oxygen molecules at the 3 and 4 positions on the molecule), but result in different hydrophobicities that could impact uptake into on the molecule), but result in different hydrophobicities that could impact uptake into and/or export from cells and the interaction targets. and/or export from cells and the interaction targets. 2. Methods 2. Methods 2.1. Reagents 2.1.
Recommended publications
  • Topical and Systemic Antifungal Therapy for Chronic Rhinosinusitis (Protocol)
    CORE Metadata, citation and similar papers at core.ac.uk Provided by University of East Anglia digital repository Cochrane Database of Systematic Reviews Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Head K, Sacks PL, Chong LY, Hopkins C, Philpott C Head K, Sacks PL, Chong LY, Hopkins C, Philpott C. Topical and systemic antifungal therapy for chronic rhinosinusitis. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No.: CD012453. DOI: 10.1002/14651858.CD012453. www.cochranelibrary.com Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. TABLE OF CONTENTS HEADER....................................... 1 ABSTRACT ...................................... 1 BACKGROUND .................................... 1 OBJECTIVES ..................................... 3 METHODS ...................................... 3 ACKNOWLEDGEMENTS . 8 REFERENCES ..................................... 9 APPENDICES ..................................... 10 CONTRIBUTIONSOFAUTHORS . 25 DECLARATIONSOFINTEREST . 26 SOURCESOFSUPPORT . 26 NOTES........................................ 26 Topical and systemic antifungal therapy for chronic rhinosinusitis (Protocol) i Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. [Intervention Protocol] Topical and systemic antifungal therapy for chronic rhinosinusitis Karen Head1, Peta-Lee Sacks2, Lee Yee Chong1, Claire Hopkins3, Carl Philpott4 1UK Cochrane Centre,
    [Show full text]
  • Certain Pharmaceuticals and Intermediate Chemicals: Identification of Applicable 6-Digit HS Subheadings for Products Covered By
    Second Interim Report to the Public on CERTAIN PHARMACEUTICALS AND INTERMEDIATE CHEMICALS: IDENTIFI­ CATION OF APPLICABLE 6-DIGIT HS SUBHEADINGS. .· FOR PRODUCTS ·coVERED BY THE PROPOSED URUGUAY ROUND PHARMACEUTICAL A,GREEMENT Investigation No. 332-322 USITC PUBLICATION 2500 APRIL 1992 ,f~· United States International Trade Commission . ·J, Washington, DC 20436 . ·-~}~~:; . _:, -~;<$f ·!•;. UNITED STATES INTERNATIONAL TRADE COMMISSION COMMISSIONERS Don E. Newquist, Chairman Anne E. Brunsdale, Vice Chairman David B. Rohr Carol T. Crawford Janet A. Nuzum Peter S. Watson Office of Operations Charles W. Ervin, Director Office of Industries Rohen A. Rogowsky, Director This report was prepared principally by Eli?.abcth R. Ncsbiu Project Leader Aimison Jonnard Edward Matusik David Michels James Raftery Office of Industries David Beck Office of Tariff Affairs and Trade Agreements With assistance from Paul Daniels James Gill Office ofInformation Resources Management Under the direction of John J. Gersic, Chief Energy & Chemicals Division and Edmund D. Cappuccilli, Chief Energy, Petroleum, Benzenoid Chemicals, and Rubber and Plastics Branch · Energy & Chemicals Division Additional assistance provided by Brenda Carroll and Keilh Hipp With special assistance from U.S. Customs Service Address all communications to Kenneth R. Mason, Secreta·ry to the Commission United States International Trade Commission Washington, DC 20436 PREFACE This report is the second of two interim reports to the public pertaining to Commission investigation No. 332-322, entitled Certain Pharmaceuticals and Intermediate Chemicals; Identification of Applicable 6-Digit HS Subheadings for Products Covered by the Proposed Uruguay Round Pharmaceutical Agreement. The investigation was instituted following receipt of a letter from the United States Trade Representative (USTR) on January 27, 1992, requesting that the Commission conduct an investigation under section 332(g) of the Tariff Act of 1930 (see appendix A for a copy of the USTR' s request)·.
    [Show full text]
  • Discovery of New Antimicrobial Agents Using Combinatorial Chemistry
    Wright State University CORE Scholar Browse all Theses and Dissertations Theses and Dissertations 2007 Discovery of New Antimicrobial Agents using Combinatorial Chemistry William I. Northern Wright State University Follow this and additional works at: https://corescholar.libraries.wright.edu/etd_all Part of the Immunology and Infectious Disease Commons, and the Microbiology Commons Repository Citation Northern, William I., "Discovery of New Antimicrobial Agents using Combinatorial Chemistry" (2007). Browse all Theses and Dissertations. 206. https://corescholar.libraries.wright.edu/etd_all/206 This Thesis is brought to you for free and open access by the Theses and Dissertations at CORE Scholar. It has been accepted for inclusion in Browse all Theses and Dissertations by an authorized administrator of CORE Scholar. For more information, please contact [email protected]. DISCOVERY OF NEW ANTIMICROBIAL AGENTS USING COMBINATORIAL CHEMISTRY A thesis submitted in partial fulfillment Of the requirements for the degree of Master of Science By WILLIAM ISAAC NORTHERN B.S., University of Cincinnati, 1982 2007 Wright State University WRIGHT STATE UNIVERSITY SCHOOL OF GRADUATE STUDIES October 29, 2007 I HEREBY RECOMMEND THAT THE THESIS PREPAIRED UNDER MY SUPERVISION BY William Isaac Northern ENTITLED Discovery of New Antimicrobial Agents Using Combinatorial Chemistry BE ACCEPTED IN PARTIAL FULFULLMENT OF THE REQUIREMENTS FOR THE DEGREE OF Master of Science ______________________________ Nancy Bigley, Ph.D. Thesis Director ______________________________ Barbara Hull, Ph.D. Department Chair Committee on Final Examination ______________________________ Nancy Bigley. Ph.D. ______________________________ Barbara Hull, Ph.D. ______________________________ Daniel Ketcha, Ph.D. ______________________________ Gerald Alter, Ph.D. ______________________________ Joseph F. Thomas, Jr., Ph.D. Dean, School of Graduate Studies ABSTRACT Northern, William Isaac.
    [Show full text]
  • Fungi P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come
    P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come Fungi P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come Fungi Biology and Applications Second Edition Editor Kevin Kavanagh Department of Biology National University of Ireland Maynooth Maynooth County Kildare Ireland A John Wiley & Sons, Ltd., Publication P1: OTA/XYZ P2: ABC JWST082-FM JWST082-Kavanagh July 11, 2011 19:19 Printer Name: Yet to Come This edition first published 2011 © 2011 by John Wiley & Sons, Ltd. Wiley-Blackwell is an imprint of John Wiley & Sons, formed by the merger of Wiley’s global Scientific, Technical and Medical business with Blackwell Publishing. Registered Office: John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK Editorial Offices: 9600 Garsington Road, Oxford, OX4 2DQ, UK The Atrium, Southern Gate, Chichester, West Sussex, PO19 8SQ, UK 111 River Street, Hoboken, NJ 07030-5774, USA For details of our global editorial offices, for customer services and for information about how to apply for permission to reuse the copyright material in this book please see our website at www.wiley.com/ wiley-blackwell. The right of the author to be identified as the author of this work has been asserted in accordance with the UK Copyright, Designs and Patents Act 1988. All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, except as permitted by the UK Copyright, Designs and Patents Act 1988, without the prior permission of the publisher.
    [Show full text]
  • Unexpected Cell Wall Alteration-Mediated Bactericidal
    Unexpected cell wall alteration-mediated bactericidal activity of the antifungal caspofungin against vancomycin-resistant Enterococcus faecium Christophe Isnard, Sara B. Hernández, François Guérin, Fanny Joalland, Didier Goux, François Gravey, Michel Auzou, David P. Enot, Pierrick Meignen, Jean-Christophe Giard, et al. To cite this version: Christophe Isnard, Sara B. Hernández, François Guérin, Fanny Joalland, Didier Goux, et al.. Un- expected cell wall alteration-mediated bactericidal activity of the antifungal caspofungin against vancomycin-resistant Enterococcus faecium. Antimicrobial Agents and Chemotherapy, American So- ciety for Microbiology, 2020, 64 (10), 10.1128/AAC.01261-20. hal-02930693 HAL Id: hal-02930693 https://hal.archives-ouvertes.fr/hal-02930693 Submitted on 15 Sep 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. 1 Unexpected cell wall alteration-mediated bactericidal activity of the 2 antifungal caspofungin against vancomycin-resistant Enterococcus faecium 3 4 Running title: In vitro activity of caspofungin against E. faecium
    [Show full text]
  • Effectiveness of 7.5 Percent Povidone Iodine in Comparison to 1 Percent Clotrimazole in the Treatment of Otomycosis
    EFFECTIVENESS OF 7.5 PERCENT POVIDONE IODINE IN COMPARISON TO 1 PERCENT CLOTRIMAZOLE IN THE TREATMENT OF OTOMYCOSIS A DISSERTATION SUBMITTED IN PARTIAL FULFILLMENT OF M.S BRANCH –IV (OTORHINOLARYNGOLOGY EXAMINATION OF THE DR.MGR. MEDICAL UNIVERSITY TO BE HELD IN APRIL 2012 ACKNOWLEDGEMENTS I wish to express my deep gratitude to Dr Anand Job, Professor and Head of Unit 1, Department of Otorhinolaryngology, Speech and Hearing, Christian Medical College and Hospital, Vellore for his able guidance and encouragement in conducting this study and preparing this dissertation. I wish to express my deep gratitude to Dr Achamma Balraj, Head of the Department of Otorhinolaryngology, Speech and Hearing, Christian Medical College and Hospital, Vellore for her able guidance and encouragement in conducting this study and preparing this dissertation. I would like to thank Dr Rita Ruby Albert, Dr Regi Thomas, and Dr Rajan Sundaresan from the Department of Otorhinolaryngology for being my co-investigators in this study. I am extremely thankful to Dr Shalini Anandan, Assistant professor, Department of Microbiology for her guidance in this study. I am thankful to Dr Selvaraj from the Department of Biostatistics for his able guidance in the statistical analysis of this study. I would like to thank the Fluid Research Committee, CMC Hospital for granting me financial assistance for conducting this study. Last but not the least; I would like to thank all my patients who participated with me in this study for their kind co-operation. CERTIFICATE This is to certify that the dissertation entitled “Effectiveness of 7.5 percent povidone iodine in comparison to 1 percent clotrimazole in the treatment of otomycosis” is a bonafide original work of Dr Ajay Philip, submitted in partial fulfillment of the rules and regulations for the MS Branch IV, Otorhinolaryngology examination of The Tamil Nadu Dr.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • View U.S. Patent Application Publication No. US-2020-0056988
    1111111111111111 IIIIII IIIII 1111111111 11111 11111 111111111111111 IIIII IIIII IIIIII IIII 11111111 US 20200056988Al c19) United States c12) Patent Application Publication c10) Pub. No.: US 2020/0056988 Al Butz et al. (43) Pub. Date: Feb. 20, 2020 (54) METHOD OF DETERMINING THE Publication Classification EFFICACY OF ANTIMICROBIALS (51) Int. Cl. GOIN 2113504 (2006.01) (71) Applicant: Wisconsin Alumni Research GOIN 33/497 (2006.01) Foundation, Madison, WI (US) (52) U.S. Cl. CPC ....... GOIN 2113504 (2013.01); GOIN 33/497 (72) Inventors: Daniel Elmer Butz, Madison, WI (US); (2013.01) Ann P. O'Rourke, Madison, WI (US); Mark E. Cook, Madison, WI (US) (57) ABSTRACT A method of determining efficacy of an antimicrobial treat­ ment in a subject includes calculating a breath delta value (21) Appl. No.: 16/540,627 (BDV) for each of at least six breath samples acquired from the subject over a 24 hour period starting from when the subject has been administered the antimicrobial treatment, (22) Filed: Aug. 14, 2019 calculating a mean standard deviation of BDV (SD BDV) across the six or more breath samples; and determining that the antimicrobial treatment is effective when the SD BDV is Related U.S. Application Data less than or equal to 0.46, or determining that the antimi­ crobial treatment is ineffective when the SD BDV is greater (60) Provisional application No. 62/764,874, filed on Aug. than 0.46. Also included are methods of treating a subject in 16, 2018. need of antimicrobial treatment. r Ass~sse~.f~;·el;~!~i!lt;·~n~~·~1)···· i ,, --~----·--··--···············r··············•······-·······•_.•.•.•.•_.•.•.•.•_J________ ___.........,., ; Excluded (no:299) r- ➔@!~;;;:~=:· ~··· Consented for partidpatfon {ir=32) Wi!hdrawn: • Exdusionary Criteria (ri=3) • Withdrawn by lnve.stigator(n"'2) Analyzed {n:=27) , Excluded from analysis {inadequate breath samples} {n=7} • 20 Subjects Anaiyze<l: o 13 Male; 7 Femi.lie o 76.2% Caucasian: VU% African American: 9.5% Other o 19% 18-35 yfo; 33_3% 36-54 yfo; 33.3% 55-73 yfo: i4.3 74+ yto Patent Application Publication Feb.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • A Abacavir Abacavirum Abakaviiri Abagovomab Abagovomabum
    A abacavir abacavirum abakaviiri abagovomab abagovomabum abagovomabi abamectin abamectinum abamektiini abametapir abametapirum abametapiiri abanoquil abanoquilum abanokiili abaperidone abaperidonum abaperidoni abarelix abarelixum abareliksi abatacept abataceptum abatasepti abciximab abciximabum absiksimabi abecarnil abecarnilum abekarniili abediterol abediterolum abediteroli abetimus abetimusum abetimuusi abexinostat abexinostatum abeksinostaatti abicipar pegol abiciparum pegolum abisipaaripegoli abiraterone abirateronum abirateroni abitesartan abitesartanum abitesartaani ablukast ablukastum ablukasti abrilumab abrilumabum abrilumabi abrineurin abrineurinum abrineuriini abunidazol abunidazolum abunidatsoli acadesine acadesinum akadesiini acamprosate acamprosatum akamprosaatti acarbose acarbosum akarboosi acebrochol acebrocholum asebrokoli aceburic acid acidum aceburicum asebuurihappo acebutolol acebutololum asebutololi acecainide acecainidum asekainidi acecarbromal acecarbromalum asekarbromaali aceclidine aceclidinum aseklidiini aceclofenac aceclofenacum aseklofenaakki acedapsone acedapsonum asedapsoni acediasulfone sodium acediasulfonum natricum asediasulfoninatrium acefluranol acefluranolum asefluranoli acefurtiamine acefurtiaminum asefurtiamiini acefylline clofibrol acefyllinum clofibrolum asefylliiniklofibroli acefylline piperazine acefyllinum piperazinum asefylliinipiperatsiini aceglatone aceglatonum aseglatoni aceglutamide aceglutamidum aseglutamidi acemannan acemannanum asemannaani acemetacin acemetacinum asemetasiini aceneuramic
    [Show full text]
  • Candida Albicans from Vaginal Ulcer and Separation of Enolase on SDS-PAGE
    Vol. 2, No. 1 International Journal of Biology Culture and Identification of Candida Albicans from Vaginal Ulcer and Separation of Enolase on SDS-PAGE P. Saravana Bhavan (Corresponding author) Department of Zoology, Bharathiar University Coimbatore 641046, Tamilnadu, India Tel: 91-422-242-2222 Ext. 495 E-mail: [email protected] R. Rajkumar PRIDE, Periyar University Salem 636011, Tamilnadu, India E-mail: [email protected] S. Radhakrishnan Department of Zoology, Bharathiar University Coimbatore 641046, Tamilnadu, India E-mail: [email protected] C. Seenivasan Department of Zoology, Bharathiar University Coimbatore 641046, Tamilnadu, India E-mail: [email protected] S. Kannan Department of Zoology, Bharathiar University Coimbatore 641046, Tamilnadu, India E-mail: [email protected] Abstract Candida albicans were isolated from patients with clinical symptoms of vaginal ulcer. Culture test for vaginal swab and scrapings were conducted on Sabouraud’s dextrose broth and Sabouraud’s dextrose agar plate respectively. Hichrome candida agar culture was used for differential identification of Candida. Smears from vaginal scrapings were prepared for gram staining. The suspected strain of Candida was inoculated on corn meal agar medium for chlamydospore formation. The suspected strain of Candida was inoculated in human serum for germ tube formation. Carbohydrate assimilation and fermentation tests were also conducted. The selected Candida colony was inoculated in YEPD medium for subculture and the cultured organism was harvested. The organisms were homogenized, centrifuged and the supernatant was filtered. The filtrate was extracted in chloroform. The extract was centrifuged and the aqueous phase was dialyzed. The dialyzed crude enolase was subjected to SDS-PAGE. The Sabouraud’s dextrose broth inoculated with vaginal swab showed turbid growth.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,605,138 B2 Krieg (45) Date of Patent: Oct
    USOO7605138B2 (12) United States Patent (10) Patent No.: US 7,605,138 B2 Krieg (45) Date of Patent: Oct. 20, 2009 (54) NUCLEICACID COMPOSITIONS FOR 6,589,940 B1 7/2003 Raz et al. STMULATING IMMUNE RESPONSES 6,610,308 B1 8, 2003 Haensler 6,610,661 B1 8, 2003 Carson et al. (75) Inventor: Arthur M. Krieg, Wellesley, MA (US) 6,653,292 B1 1 1/2003 Krieg et al. 6,727,230 B1 4/2004 Hutcherson et al. (73) Assignee: Coley Pharmaceutical Group, Inc., 6,749,856 B1 6/2004 Berzofsky et al. New York, NY (US) 6.821,957 B2 11/2004 Krieg et al. 6,835,395 B1 12/2004 Semple et al. (*) Notice: Subject to any disclaimer, the term of this 6,852,705 B2 2/2005 Audonnet et al. patent is extended or adjusted under 35 6,943,240 B2 9, 2005 Bauer et al. U.S.C. 154(b) by 732 days. 6,949,520 B1 9, 2005 Hartmann et al. 7,001,890 B1 2/2006 Wagner et al. (21) Appl. No.: 10/613,524 7,223,741 B2 5/2007 Krieg 7,271,156 B2 9/2007 Krieg et al. (22) Filed: Jul. 3, 2003 7.303,881 B2 12/2007 Huang et al. 7,354,711 B2 4/2008 Macfarlane (65) Prior Publication Data 7,354,909 B2 4/2008 Klinman et al. 7,402,572 B2 7/2008 Krieg et al. US 2004/O19868O A1 Oct. 7, 2004 7,410,975 B2 8/2008 Lipford et al. 2001/0044416 A1 11/2001 McCluskie et al.
    [Show full text]